Monday, August 24

Browsing: FiveYear

Survivors

Five-Year KEYNOTE-775 Data Confirm Durable Benefit With Lenvatinib Combo

By NewsCancerAugust 22, 20260

Susana M. Campos, MD, MPH, clinical director of the Division of Gynecologic Oncology and director of Educational Initiatives at Dana-Farber…

Diagnosis

121 Five-Year Analysis of Distant Disease-Free Survival (DDFS) Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib (RIB) Plus a Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC)

By NewsCancerMay 10, 20260

BackgroundDespite improvements in outcomes in patients with hormone receptor–positive early breast cancer, distant recurrence remains a major concern given that…

► Necessary Cookies Always Active

Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.

► Functional Cookies Remark

Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.

► Analytical Cookies Remark

Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.

► Advertisement Cookies Remark

Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.

What's Hot

Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer

<![CDATA[Efficacy Results – Complete Response and Progression-Free Survival]]>

<![CDATA[Safety and Tolerability in Older, Frail Patients With DLBCL]]>

Browsing: FiveYear

Five-Year KEYNOTE-775 Data Confirm Durable Benefit With Lenvatinib Combo

121 Five-Year Analysis of Distant Disease-Free Survival (DDFS) Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib (RIB) Plus a Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC)

Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer

<![CDATA[Efficacy Results – Complete Response and Progression-Free Survival]]>

<![CDATA[Safety and Tolerability in Older, Frail Patients With DLBCL]]>

<![CDATA[Toward Chemo-Free Regimens – What's Next for DLBCL Treatment]]>

Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer

<![CDATA[Efficacy Results – Complete Response and Progression-Free Survival]]>

<![CDATA[Safety and Tolerability in Older, Frail Patients With DLBCL]]>

<![CDATA[Toward Chemo-Free Regimens – What's Next for DLBCL Treatment]]>

Latest Post

Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer

<![CDATA[Efficacy Results – Complete Response and Progression-Free Survival]]>

<![CDATA[Safety and Tolerability in Older, Frail Patients With DLBCL]]>

Subscribe to Updates

What's Hot

Browsing: FiveYear